Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables (2018 - 2025)

China SXT Pharmaceuticals has reported Receivables over the past 8 years, most recently at $1.5 million for Q3 2025.

  • For Q3 2025, Receivables rose 582.96% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, up 582.96%, while the annual FY2025 figure was $3.8 million, 171.83% up from the prior year.
  • Receivables for Q3 2025 was $1.5 million at China SXT Pharmaceuticals, down from $1.7 million in the prior quarter.
  • Over five years, Receivables peaked at $4.7 million in Q1 2021 and troughed at -$303261.0 in Q3 2024.
  • A 5-year average of $2.1 million and a median of $1.6 million in 2025 define the central range for Receivables.
  • Biggest five-year swings in Receivables: crashed 315.6% in 2024 and later surged 582.96% in 2025.
  • Year by year, Receivables stood at $697805.0 in 2021, then surged by 376.22% to $3.3 million in 2022, then crashed by 102.2% to -$72969.0 in 2023, then crashed by 315.6% to -$303261.0 in 2024, then surged by 582.96% to $1.5 million in 2025.
  • Business Quant data shows Receivables for SXTC at $1.5 million in Q3 2025, $1.7 million in Q1 2025, and -$303261.0 in Q3 2024.